Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs).

Next Previous
Search
Trial Profile

A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs).

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TACT-2C

Most Recent Events

  • 16 Feb 2018 Status changed from recruiting to discontinued.
  • 01 Apr 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top